Emtora Biosciences

Executive Summary

Emtora Biosciences is a San Antonio-based clinical-stage biopharmaceutical company developing eRapa, a novel oral formulation of rapamycin designed to improve bioavailability and tolerability compared to traditional rapamycin. The company focuses on harnessing mTOR inhibition for the prevention and treatment of cancer and rare genetic diseases. Its lead program targets Familial Adenomatous Polyposis (FAP), a condition that frequently progresses to colorectal cancer, as well as early-stage cancers and other mTOR-driven disorders. eRapa's differentiated delivery system aims to achieve sustained efficacy while reducing side effects, positioning it as a potential best-in-class therapy in the mTOR-inhibitor landscape. The company has advanced eRapa into clinical trials and expects to report key data from its ongoing Phase 2 study in FAP patients in the coming quarters. Positive results could support a regulatory pathway for FAP, an indication with no approved pharmacologic options. Additionally, Emtora is exploring eRapa in other solid tumors, with early-stage trials evaluating safety and preliminary efficacy. As a private entity, Emtora may also seek strategic partnerships or additional financing to expand its pipeline and accelerate development. The company's focused strategy and novel formulation technology provide a targeted approach to addressing high unmet medical needs in both oncology and rare diseases.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for eRapa in Familial Adenomatous Polyposis (FAP)60% success
• Q4 2026Initiation of Phase 2 trial for eRapa in early-stage colorectal cancer or other solid tumors70% success
• H2 2026Strategic partnership or financing agreement to support clinical development50% success